• MIRA Pharmaceuticals reported initial pilot-study results showing oral obesity candidate SKNY-1 reduced weight and fat in obese mice versus vehicle controls.
• Weight reduction occurred without significantly lower food intake, suggesting a potential metabolic effect beyond appetite suppression.
• SKNY-1 showed no significant lean-mass loss versus controls, unlike the semaglutide reference group.
• Weight regain remained limited during two weeks following treatment cessation, compared with rapid, substantial rebound with semaglutide.
• Longer-term preclinical studies will assess metabolic effects as development work continues toward future clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-048978), on October 28, 2026, and is solely responsible for the information contained therein.